Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML - European Medical Journal

Continue

Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML

Oncology
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free survival and relapse-free survival in younger patients with acute myeloid leukaemia (AML).

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.